On March 10, 2025, Imeik Technology Development Co., Ltd. (“IMEIK”, stock code: 300896.SZ) announced its plan to acquire an 85% stake in REGEN Biotech, Inc. (“REGEN”), a Korean company, through its subsidiary, Imeik International Limited (“IMEIK International”). The purchase price for the 85% stake is approximately $190 million, with the remaining REGEN shares set to be acquired within the next 18 months. IMEIK’s board of directors has approved the share purchase agreement between IMEIK International and the transaction counterparties.

IMEIK is a leading innovative company specializing in the research, development, and commercialization of biomaterials and biopharmaceutical products. As one of the earliest enterprises in China to engage in independent R&D and application of biomedical materials for medical aesthetics, IMEIK has strategically built a comprehensive presence in the industry, spanning product, technology, service, and ecosystem. It stands as a leading provider of innovative medical aesthetic products in China.

The acquisition target, REGEN, focuses on the research, production, and sales of medical materials, medical devices, and pharmaceutical products. Its core products include regenerative injectable fillers, which have been registered and approved in 34 countries and regions, supported by an extensive distribution network. This transaction marks a critical step in IMEIK’s internationalization strategy, further solidifying its leadership in the dermal filler market, enhancing profitability and core competitiveness, and driving sustainable future growth.

AnJie Broad Law Firm advised IMEIK on its cross-border acquisition, leveraging its strong cross-border integration capabilities and deep expertise in the medical aesthetics industry. The firm provided end-to-end legal support, ensuring the successful execution of the acquisition agreement between IMEIK and its counterparties.

AnJie Broad played a pivotal role in structuring the transaction, negotiating and refining English-language deal documents, and collaborating with overseas counsels, including Korea’s LIN, to conduct a thorough legal due diligence review of the target company. The team’s professionalism, diligence, and efficiency were instrumental in closing the transaction, earning high praise from the client.

The AnJie Broad legal team was led by Partners LIU Hongchuan, CHEN Huan, WEN Yijun, with team members including YAN Fang, XI Yuqi and WANG Xinman.